← Back to Patent Explorer
US4176185A Expired / Lapsed US ⏱️ 0.0 years remaining

Spiro-quinolylhydantoins

Assignee: Pfizer Inc
•
Filing: 1979-01-22
•
Granted: 1979-11-27
•
Expires: 1999-01-22
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Novel spiro-quinolylhydantoin derivatives useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. Preferred compounds include spiro[imidazolidin-4,4'-pyrano[3,2-h]quinolin]-2,5-dione and spiro[imidazolidin-4,4'-pyrano[2,3-f]quinolin]-2,5-dione.

Inventors

  • 👤 Rodney C. Schnur

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 14:20
CPC Classifications
C; C07; C07D; C07D491/00; C07D491/02; C07D491/04; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61P; A61P25/00; A61P25/18; A61P27/00; A61P27/02; A61P27/12; A61P3/00; A61P3/08; A61P3/10; A61P43/00; C07D215/00; C07D215/02; C07D215/16; C07D215/20; C07D215/24; C07D215/26; C07D491/12; C07D491/20; C07D495/00; C07D495/12; C07D495/20

Claims Analysis

Total Claims: 18
Claim 1
Independent Claim 77 words
A compound selected from the formulae ##STR3## and the base salts thereof with pharmaceutically acceptable cations, wherein X is selected from oxygen and sulfur; n is zero, one or two; R is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and benzyl; and R 1 , R 2 and R 3 are each selected from the group consisting of hydrogen, chloro, bromo, fluoro and alkyl of 1 to 3 carbon atoms.
Claim 2
Dependent Claim 77 words
A compound selected from the formulae ##STR3## and the base salts thereof with pharmaceutically acceptable cations, wherein X is selected from oxygen and sulfur; n is zero, one or two; R is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and benzyl; and R 1 , R 2 and R 3 are each selected from the group consisting of hydrogen, chloro, bromo, fluoro and alkyl of 1 to 3 carbon atoms.
Claim 3
Dependent Claim 7 words
A compound of claim 1, formula I.
Claim 4
Dependent Claim 9 words
A compound of claim 2 wherein X is oxygen.
Claim 5
Dependent Claim 9 words
A compound of claim 3 wherein n is one.
Claim 6
Dependent Claim 9 words
A compound of claim 4 wherein R is hydrogen.
Claim 7
Dependent Claim 17 words
A compound of claim 5 wherein R 1 , R 2 and R 3 are each hydrogen.
Claim 8
Dependent Claim 7 words
A compound of claim 1, formula II.
Claim 9
Dependent Claim 9 words
A compound of claim 7 wherein X is oxygen.
Claim 10
Dependent Claim 9 words
A compound of claim 8 wherein n is one.
Claim 11
Dependent Claim 9 words
A compound of claim 9 wherein R is hydrogen.
Claim 12
Dependent Claim 17 words
A compound of claim 10 wherein R 1 , R 2 and R 3 are each hydrogen.
Claim 13
Dependent Claim 26 words
A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of claim 1 in an amount effective for the treatment of diabetic cataracts, neuropathy or retinopathy.
Claim 14
Dependent Claim 31 words
A pharmaceutical composition of claim 12 wherein said compound is of formula I, X is oxygen, n is one, R, R 1 , R 2 and R 3 are each hydrogen.
Claim 15
Dependent Claim 31 words
A pharmaceutical composition of claim 12 wherein said compound is of formula II, X is oxygen, n is one, R, R 1 , R 2 and R 3 are each hydrogen.
Claim 16
Dependent Claim 28 words
A method of treating a diabetic host for diabetic cataracts, neuropathy or retinopathy which comprises administering to said host an effective amount of a compound of claim 1.
Claim 17
Dependent Claim 31 words
A method according to claim 15 wherein said compound is of formula I, X is oxygen, n is one, R, R 1 , R 2 and R 3 are each hydrogen.
Claim 18
Dependent Claim 31 words
A method according to claim 15 wherein said compound is of formula II, X is oxygen, n is one, R, R 1 , R 2 and R 3 are each hydrogen.

References Cited (Backward Citations)

DE1135915B Cited
US3876659A Cited
US4117230A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-11-26 1983-05-28 1983-11-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-11-26 1987-05-28 1987-11-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-11-26 1991-05-28 1991-11-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag